gsk719125
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2003 (NCT00058526)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk719125
- sb719125
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00140738 | Phase 1 | Mar 10, 2005 | GlaxoSmithKline |
| NCT00058526 | Phase 1 | Mar 20, 2003 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 2003 |
1 organizations
Page 1 / 1